Toxicity of combined targeted therapy and concurrent radiotherapy in metastatic melanoma patients: a single-center retrospective analysis-Reference-Cited by-同舟云学术

Toxicity of combined targeted therapy and concurrent radiotherapy in metastatic melanoma patients: a single-center retrospective analysis

Published:2020-07-08 Issue:6 Volume:30 Page:552-561
ISSN:0960-8931
Container-title:Melanoma Research
language:en
Short-container-title:

Author:

Ziegler Johanna S.,Kroeze Stephanie,Hilbers Marie-Luise,Imhof Laurence,Guckenberger Matthias,Levesque Mitchell P.,Dummer Reinhard,Cheng Phil,Mangana Joanna

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Dermatology,Oncology

Reference42 articles.

1. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.;Ascierto;Lancet Oncol,2016

2. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.;Dummer;Lancet Oncol,2018

3. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.;Larkin;N Engl J Med,2014

4. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.;Long;Ann Oncol,2017

5. Systemic treatments for metastatic cutaneous melanoma.;Pasquali;Cochrane Database Syst Rev,2018

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systemic Treatment of Melanoma;Rook's Textbook of Dermatology;2024-03-19

2. Which is the best treatment for melanoma brain metastases? A Bayesian network meta-analysis and systematic review;Critical Reviews in Oncology/Hematology;2024-02

3. Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive BRAF Mutant Advanced Melanoma;Biomedicines;2023-01-29

4. Radiotherapy and newly approved cancer drugs – A quantitative analysis of registered protocols for drugs approved for the treatment of solid tumors;Radiotherapy and Oncology;2022-03

5. Continued versus Interrupted Targeted Therapy during Metastasis-Directed Stereotactic Radiotherapy: A Retrospective Multi-Center Safety and Efficacy Analysis;Cancers;2021-09-24